MedTrace Logo

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets

NCT07710326 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-07-17

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multiple ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.

Conditions

  • Healthy Volunteers

Interventions

DRUG

VV261 900mg TID group

6 participants receive VV261 100mg 9 tablets,three times daily,orally; 2 participants will receive placebo,orally

DRUG

VV261 600mg TID group

6 participants receive VV261 100mg 6 tablets,three times daily,orally; 2 participants will receive placebo,orally

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07710326 on ClinicalTrials.gov